Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein GraftsResults From the Randomized DELAYED RRISC Trial
Paul Vermeersch, MD1,
Pierfrancesco Agostoni, MD1,*,
Stefan Verheye, MD, PhD,
Paul Van den Heuvel, MD,
Carl Convens, MD,
Frank Van den Branden, MD,
Glenn Van Langenhove, MD, PhD DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators
Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Antwerp, Belgium.
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Survival Curves
Kaplan-Meier estimates for survival by type of randomized stent (dotted blue line = bare-metal stent [BMS]; continuous red line = sirolimus-eluting stent [SES]).
|
|
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 TVR-Free Survival Curves
Kaplan-Meier estimates for target vessel revascularization (TVR)-free survival by type of randomized stent (dotted blue line = BMS; continuous red line = SES). Abbreviations as in Figure 1.
|
|
|
